GLIDR-mediated regulation of tumor malignancy and cisplatin resistance in non-small cell lung cancer via the miR-342-5p/PPARGC1A axis
GLIDR is a prognostic marker for cisplatin treatment in NSCLC and a therapeutic target in cisplatin-resistant NSCLC. GLIDR promotes NSCLC progression by sponging miR-342-5p to regulate PPARGC1A expression and regulates cisplatin resistance through the miR-342-5p/PPARGC1A axis, underscoring its potential as a therapeutic target in cisplatin-resistant NSCLC.
Authors
- Yueshi Liu
- Shu Wang (ORCID: https://orcid.org/0000-0001-8781-2535)
- Jiemin Wang (ORCID: https://orcid.org/0000-0002-6221-6363)
- Lichun Zhang (ORCID: https://orcid.org/0000-0001-8935-286X)
- Haiquan Yu (ORCID: https://orcid.org/0000-0002-6342-9125)
- Xiangnan Li (ORCID: https://orcid.org/0000-0002-3789-2861)
- Ruihua Liu (ORCID: https://orcid.org/0000-0001-5939-1964)
Institutions
- Inner Mongolia University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1186/s12885-024-12845-y
- Citations
- 2
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Natural Science Foundation of China
- Science and Technology Major Project of Inner Mongolia